# OnCo record ensem-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/ensem-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "ensem-therapeutics" ;
  schema:name "Ensem Therapeutics"@en ;
  schema:description "Ensem Therapeutics designs small-molecule medicines with computer modelling. Its lead drug, ETX-636, blocks a faulty version of the PI3K-alpha protein and is in an early trial in advanced breast cancer and other solid tumours."@en ;
  schema:url <https://onco.cc/companies/ensem-therapeutics/>, <https://ensemtx.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://ensemtx.com/>, <https://ensemtx.com/science/pipeline/>, <https://ensemtx.com/ensem-therapeutics-a-cbc-group-incubated-biopharma-company-raises-67-million-in-series-a-financing-to-develop-small-molecule-medicines-for-difficult-to-drug-targets-2/> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/ai-computation/> ;
  onco:technologies <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/>, <https://onco.cc/technologies/ai-drug-design/> ;
  onco:targets <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/wrn/>, <https://onco.cc/targets/cdk2/> ;
  onco:trials <https://onco.cc/trials/nct06993844/> .